BR112018000059A2 - compostos terapêuticos e composições para tratar transtornos sociais e transtornos de uso de sustâncias - Google Patents

compostos terapêuticos e composições para tratar transtornos sociais e transtornos de uso de sustâncias

Info

Publication number
BR112018000059A2
BR112018000059A2 BR112018000059A BR112018000059A BR112018000059A2 BR 112018000059 A2 BR112018000059 A2 BR 112018000059A2 BR 112018000059 A BR112018000059 A BR 112018000059A BR 112018000059 A BR112018000059 A BR 112018000059A BR 112018000059 A2 BR112018000059 A2 BR 112018000059A2
Authority
BR
Brazil
Prior art keywords
disorders
compositions
substance use
therapeutic compounds
treating
Prior art date
Application number
BR112018000059A
Other languages
English (en)
Other versions
BR112018000059B1 (pt
Inventor
Hicks Callum
Stewart Mcgregor Iain
Kassiou Michael
Thomas BOWEN Michael
Jorgensen William
Original Assignee
Univ Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015902659A external-priority patent/AU2015902659A0/en
Application filed by Univ Sydney filed Critical Univ Sydney
Publication of BR112018000059A2 publication Critical patent/BR112018000059A2/pt
Publication of BR112018000059B1 publication Critical patent/BR112018000059B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

são aqui descritos compostos, as composições e os métodos para o tratamento de distúrbios neurológicos, psiquiátricos, que são caracterizados por uma ruptura fundamental do comportamento social e transtornos do uso de substâncias. em particular, estes compostos são de fórmula (i), ou sais ou pró-drogas dos mesmos. os métodos de tratamento ou prevenção de distúrbios neurológicos, psiquiátricos, usando compostos de fórmula (i), ou sais e pró-drogas, são também descritos.
BR112018000059-0A 2015-07-06 2016-07-06 Compostos terapêuticos e composições para tratar transtornos sociais e transtornos de uso de substâncias BR112018000059B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015902659 2015-07-06
AU2015902659A AU2015902659A0 (en) 2015-07-06 Therapeutic compounds and compositions for treating social disorders and substance use disorders
PCT/AU2016/050588 WO2017004674A1 (en) 2015-07-06 2016-07-06 Therapeutic compounds and compositions for treating social disorders and substance use disorders

Publications (2)

Publication Number Publication Date
BR112018000059A2 true BR112018000059A2 (pt) 2018-09-04
BR112018000059B1 BR112018000059B1 (pt) 2023-08-22

Family

ID=

Also Published As

Publication number Publication date
CN107922420B (zh) 2021-12-31
AU2016289271A1 (en) 2018-01-25
EP3328864B1 (en) 2022-09-07
JP7490018B2 (ja) 2024-05-24
PL3328864T3 (pl) 2023-02-27
DK3328864T3 (da) 2022-12-05
IL256684B (en) 2022-06-01
US11890287B2 (en) 2024-02-06
MX2017017171A (es) 2018-04-30
IL256684A (en) 2018-03-29
HK1252813A1 (zh) 2019-06-06
US20220362261A1 (en) 2022-11-17
HUE060496T2 (hu) 2023-03-28
KR20180023992A (ko) 2018-03-07
SI3328864T1 (sl) 2023-02-28
NZ738672A (en) 2022-11-25
JP2018525351A (ja) 2018-09-06
JP2022130418A (ja) 2022-09-06
CA2991236A1 (en) 2017-01-12
RU2018103873A3 (pt) 2019-09-04
EP3328864A1 (en) 2018-06-06
RU2715384C2 (ru) 2020-02-27
AU2016289271B2 (en) 2020-12-03
RU2018103873A (ru) 2019-08-06
US11033555B2 (en) 2021-06-15
CN107922420A (zh) 2018-04-17
US20190290658A1 (en) 2019-09-26
EP3328864A4 (en) 2019-01-09
ES2932194T3 (es) 2023-01-16
PT3328864T (pt) 2022-12-07
WO2017004674A1 (en) 2017-01-12
JP7089825B2 (ja) 2022-06-23

Similar Documents

Publication Publication Date Title
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
BR112022004451A2 (pt) Antagonistas de hpk1 e usos dos mesmos
BR112018069612A2 (pt) compostos de pirroltriazina como inibidores de tam
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
BR112017009648A2 (pt) composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
BR112017009657A2 (pt) análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
BR112016029612A2 (pt) compostos de di-hidroisoquinolinona substituídos
BR112016017996A2 (pt) 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112017004741A2 (pt) compostos e composições como inibidores da raf quinase
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
BR112018007664A2 (pt) antagonistas de ep4
MX2017017171A (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112017000520A2 (pt) composto ou sal do mesmo, uso um composto ou de um sal, e, kit.
BR112016022749A2 (pt) compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/07/2016, OBSERVADAS AS CONDICOES LEGAIS